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ABSTRACT
Objectives To establish evidence- based 
recommendations to guide health professionals using 
intra- articular therapies (IAT) in adult patients with 
peripheral arthropathies.
Methods A multidisciplinary international task force 
established the objectives, users and scope and the need 
for background information, including systematic literature 
reviews) and two surveys addressed to healthcare 
providers and patients throughout Europe. The evidence 
was discussed in a face- to- face meeting, recommendations 
were formulated and subsequently voted for anonymously 
in a three- round Delphi process to obtain the final 
agreement. The level of evidence was assigned to each 
recommendation with the Oxford levels of evidence.
Results Recommendations focus on practical aspects 
to guide health professionals before, during and after 
IAT in adult patients with peripheral arthropathies. 
Five overarching principles and 11 recommendations 
were established, addressing issues related to patient 
information, procedure and setting, accuracy, routine and 
special aseptic care, safety issues and precautions to be 
addressed in special populations, efficacy and safety of 
repeated joint injections, use of local anaesthetics and 
aftercare.
Conclusion We have developed the first evidence 
and expert opinion- based recommendations to 
guide health professionals using IAT. We hope that 
these recommendations will be included in different 
educational programmes, used by patient associations 
and put into practice via scientific societies to help 
improve uniformity and quality of care when performing 
IAT in peripheral adult joints.
INTRODUCTION
Intra- articular therapy (IAT) is a cornerstone proce-
dure extensively performed by different health 
professionals around the world. IAT is a key for 
treating adults with joint synovitis, effusion and 
pain of different origins such as inflammatory 
arthritis and osteoarthritis (OA).1 Common inject-
ables include glucocorticoids (GC), local anaes-
thetics, hyaluronic acid (HA), autologous blood 
products and radiopharmaceuticals.2–7 Regardless 
of their efficacy and safety tested in clinical trials, in 
daily practice, a myriad of aspects may influence the 
outcome of IATs, such as the specific arthropathy, 
joint location and size, the setting and the proce-
dure as well as the postprocedure care.
There is a wide variation in the way IAT are used 
and delivered in patients with arthropathies.8 9 
Health professionals may have different views and 
habits depending on training and access to IATs, 
and individual patients also have their own needs 
and preferences.9 10
To the best of our knowledge, no international 
and multidisciplinary effort has been made to 
develop evidence- based recommendations when 
performing IAT. To address this gap, EULAR (Euro-
pean alliance of associations for Rheumatology) 
established a taskforce with the aim of developing 
evidence- based recommendations to help guide 
health professionals using IAT in adult patients with 
peripheral arthropathies.
METHODS
The project adhered to the updated EULAR stan-
dardised operating procedures for the development 
of recommendations.11 Methods included two 
face- to- face meetings, a series of systematic reviews 
(SR) and the production of Delphi technique- based 
consensual recommendations.
The task force (TF) comprised a convenor (JU), 
co- convenor (EN), methodologist (LC), 2 fellows 
(SCR- G and RC- M), 12 clinical experts from six 
European countries (rheumatologist, orthopaedic 
surgeon, nuclear medicine specialist and radiol-
ogist), 2 of whom belonged to EMEUNET (VV 
and ENi), 1 rheumatology nurse (JdlT- A), and one 
patient representative (IAP).
At the first face- to- face meeting, after presenting 
the evidence of an overview SR on the efficacy and 
safety of IAT,12 the TF established the aims and 
scope and defined the functions, tasks and timing 
of the work programme, then prepared 32 ‘PICO’ 
(population–intervention–comparator–outcome) 
questions relating to the topic area and carried out 
a ranking exercise to define priorities. To address 
the PICO questions, a series of SR were undertaken 
by the fellows under the supervision of the meth-
odologist and the convenors, while an experienced 
librarian helped with the search strategies. Evidence 
was approached hierarchically by first identifying 
existing SR, appraising them using the AMSTAR-2 
tool13 and subsequently identifying and appraising 
individual studies in the situations where an SR to 
address a particular PICO question was not avail-
able. The results of the SR are being published 
elsewhere.12
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To understand the patient’s perspectives on IAT, a 44- item 
survey was developed, translated into 11 languages and dissem-
inated to patients with rheumatic disease and their carers via 
the EULAR people with arthritis and rheumatism associations 
and via social media. To understand current clinical practice, a 
160- item survey was developed and disseminated to a range of 
healthcare professionals via EULAR professional associations 
and social media. The results of these surveys will be published 
separately.14 At the second face- to- face meeting, we discussed 
the evidence obtained from the SRs and surveys and formulated 
individual recommendations. These tentative recommendations 
were discussed and consequently rephrased if necessary. Then 
the agreement for each recommendation was anonymously 
tested in a first Delphi round from 0 to 10. Recommendations 
with an agreement greater than 65% were included for the next 
round. Those that did not reach 65% agreement were discarded 
and not included in the second round. One month after the 
second meeting, the third Delphi round was run electronically 
using SurveyMonkey. To remain in the set of recommendations 
after the second round, agreement needed to be greater than 
80%. Finally, the methodologist added the level of evidence and 
grade of recommendation to each statement, according to the 
Oxford levels of evidence.15
The manuscript draft was reviewed by all TF members and 
pertinent comments were included. After that, it was submitted 
to the EULAR executive committee for review and approval.
RESULTS
Aim, users and scope
The TF agreed to establish recommendations to guide all health-
care professionals on practical aspects when undertaking IAT in 
adults with peripheral arthropathies. It was agreed that they would 
not include recommendations about use of individual therapies in 
specific diseases, for which guidelines currently exist.
Evidence results
The fellows addressed 32 PICO questions (see online supplemental 
table 1). An overview of SR of randomised controlled trials (RCTs) 
was performed up to July 2020 12 The results from the other SRs 
that support specific recommendations are presented with the 
recommendation.
For the surveys, 200 patients responded and the results 
suggested a number of aspects about IAT that could be improved, 
including, for example, wider availability of IAT, attention paid 
to reduce pain from the procedure and better shared decision- 
making (SDM) including provision of information about the 
procedure.14 The health professional survey was responded by 
186 professionals, 77% of whom were rheumatologists, from 26 
countries.14 The specific results that support any recommenda-
tion are presented as supporting evidence.
Overarching principles and recommendations
The overarching principles with their agreement and the recom-
mendations together with their agreement, level of evidence and 
grade of recommendation are summarised in table 1
Overarching principles
IAT are recommended and widely used in the management of joint 
diseases.
Any treatment, including IA injectables, should be given 
according to the best practice.
Table 1 Overarching principles and recommendations, with agreement and level of evidence and grade of recommendation (if applicable)
Overarching principles A (%)
I. IAT are recommended and widely used in the management of joint diseases. 98
II.The aim of IAT is to improve patient- centred outcomes. 100
III.Contextual factors are important and contribute to the effect of IAT. 93
IV.IAT should be offered in the frame of full individualised information and a shared decision- making process. 97
V. A variety of health professionals perform these procedures routinely. 94
Recommendations A (%) LE GR
1.The patient must be fully informed of the nature of the procedure, the injectable, and potential benefits and risks; informed 
consent should be obtained and documented according to local habits.
99 4 D
 ► An optimal setting for IAT includes:Professional, clean, quiet, private, well- lightened room.
 ► Patient in an appropriate position, ideally on a couch/examination table, easy to lie flat.
 ► Equipment for aseptic procedures.
 ► Aid from another HP.
 ► Resuscitation equipment close- by.
85 4 D
3.Accuracy depends on the joint, route of entry, and health professional expertise; if available, imaging guidance, for 
example, ultrasound, may be used to improve accuracy.
93 1B- 2A B
4.During pregnancy when injecting a joint one has to take into account whether the compound is safe for mother and baby. 98 4 D
5.Aseptic technique should always be undertaken when performing IAT. 98 3 C
6.Patients should be offered local anaesthetic explaining pros and cons. 75 3–4 D
7.Diabetic patients, especially those with suboptimal control, should be informed about the risk of transient increased 
glycaemia following IA GC and advised about the need to monitor glucose levels particularly from first to third day.
97 1B A
8.IAT is not a contraindication in people with clotting/bleeding disorders or taking antithrombotic medications, unless 
bleeding risk is high.
89 3 C
9.IAT may be performed at least 3 months prior to joint replacement surgery, and may be performed after joint replacement 
following consultation with the surgical team.
88 3 C
10.The shared decision to reinject a joint should take into consideration benefits from previous injections and other 
individualised factors (eg, treatment options, compound used, systemic treatment, comorbidities…).
93 2 B
11.Avoid overuse of injected joints for 24 hours following IAT; however, immobilisation is discouraged. 94 1B A
A, agreement; GR, grade of recommendation; IAGC, intra- articular glucocorticoids; IAT, intra- articular therapies; LE, level of evidence.
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Dose and approach need to be defined for each indication 
and joint and might not be interchangeable across indications. 
Table 2 shows current EULAR recommendations in which IAT 
are mentioned.
The aim of IAT is to improve patient-centred outcomes.
Patient- centred outcomes are those relevant to the patient, such as 
benefits, harms, preferences or implications for self- management. 
While injectables are used mainly as a treatment to improve patient- 
centred outcomes, they can also be used to aid diagnosis and identify 
the origin of pain (eg, lidocaine test may be used to rule out joint 
vs referred pain).1 The objective of therapy should be among the 
expected outcomes based on evidence. An example of an unclear 
objective is to use injectables to improve function in a joint without 
pain. Reduction of systemic medication can be also considered a 
patient and health provider aim.
Contextual factors are important and contribute to the effect of IAT.
Contextual factors such as effective communication, patient 
expectations or the setting in which the procedure takes place, 
which may influence the outcome of IAT. Additionally, one 
should recognise the magnitude of the placebo effect associated 
with this route of delivery.16
IAT should be offered in the frame of full individualised information 
and a SDM process
SDM implies the involvement of patients with their providers in 
making healthcare decisions that are informed by the best avail-
able evidence about options, potential benefits and harms, and 
that consider patient preferences. If not within a framework of 
SDM, any recommendation may not reach the expected effect.
A variety of health professionals perform these procedures routinely.
Depending on country regulations, IAT can be carried out by 
general practitioners, rheumatologists, traumatologists/ortho-
paedic surgeons, sports medicine specialists, radiologists, nuclear 
medicine specialists, trained nurses, physical therapists and occu-
pational therapists, with varying levels of formal training.14
Recommendations
The patient must be fully informed of the nature of the procedure, 
the injectable and potential benefits and risks; informed consent 
should be obtained and documented according to local habits.
The TF agreed to include this general statement as the first recom-
mendation on the basis that this frequent procedure is delivered by 
health professionals from many countries and that patients surveyed 
wanted to be informed prior to consent as an essential part of 
the SDM process.14 Whether informed consent should be oral or 
written is beyond the scope of this project, furthermore, there was 
no preferred option in the patient survey. Essential information to be 
delivered includes the nature of the procedure, the potential benefit, 
side effects and postinjection care.
An optimal setting for IAT includes a professional clean quiet private 
well-lightened room, the patient in an appropriate position, ideally 
on a couch/examining table, easy to lie flat, equipment for aseptic 
procedures, aid from another HP and resuscitation equipment close 
by.
Contextual effects including the setting in which clinical care 
is delivered may impact on the outcome of clinical interven-
tions. We could not identify any studies to help inform what 
the optimal setting for undertaking IAT therapy is. However, all 
these aspects may enhance the contextual effect. It was agreed 
that the main equipment required was a couch/examining table 
which could be adjusted, and equipment for aseptic procedures 
and resuscitation equipment close by. There was a discussion 
about the need to have another HP present as many countries 
or centres do not provide assistants.14 A retrospective case series 
analysis showed a 2.6% overall rate for vasovagal reactions,17 
which may justify the help of others; however, in the healthcare 
professional survey, the large majority of professionals said that 
they never or seldom had vasovagal reactions.14
Accuracy depends on the joint, route of entry and health 
professional expertise; if available, imaging guidance, for example, 
ultrasound, may be used to improve accuracy.
Several published SRs and RCTs report that ultrasound improves 
accuracy in delivery of IAT though clinical outcomes are similar 
to those of landmark- guided IAT.18–21 When using anatomical 
landmarks (blinded injections), each peripheral joint has different 
routes of entry. The best approach for a certain joint cannot be 
recommended except for the knee in which an SR showed that 
the superolateral approach was more common and resulted in 
the highest pooled accuracy rate of 91% (95% CI 84% to 99%) 
in patients with different arthropathies.22 Aspiration of synovial 
fluid helps ensure that the needle is in the joint.23 24 Expertise 
in the procedure is important and appreciated by the patient, as 
highlighted in the survey, and it is clearly dependent on practice 
and appropriate training.14 25
Table 2 Eular recommendations in which IAT are mentioned
Joint/condition EULAR recommendation
Knee osteoarthritis86 ‘Intra- articular injection of long acting GC is indicated for acute exacerbation of knee pain, especially if accompanied by 
effusion.’
‘Hyaluronic acid (…) is probably effective in knee OA, but the size effect is relatively small, suitable patients are not well 
defined, and pharmacoeconomic aspects of that treatment are not well established’.
Gout16 ‘Recommended first- line options for acute flares are colchicine (…), oral corticosteroid (…) or articular aspiration and 
injection of corticosteroids.’
Rheumatoid arthritis87 88 ‘Monitoring should be frequent (…) therapy should be adjusted.’
*Adjustment of therapy includes the optimisation of MTX (or other csDMARD) dose or route of administration, or intra- 
articular injections of GC in the presence of one or few residual active joints.
Hand osteoarthritis89 90 ‘Intra- articular injections of glucocorticoids should not generally be used in patients with hand OA, but may be considered in 
patients with painful interphalangeal joints’.
Acute or recent onset swelling of the knee91 ‘Intra- articular steroids should not be administered unless an appropriate diagnosis has been made and contraindications 
have been ruled out’.
csDMARD, conventional synthetic disease- modifying antirheumatic drugs ; GC, glucocorticoids; MTX, methotrexate; OA, osteoarthritis.
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During pregnancy when injecting a joint one has to take into 
account whether the compound is safe for mother and baby.
IAT during pregnancy is often performed to treat local arthritis 
when indicated and the benefit/risk ratio in this setting may be 
superior to that for systemic therapy. Most of the compounds in 
routine practice can be used except for radiopharmaceuticals, 
which are contraindicated during pregnancy.
Aseptic technique should always be undertaken when performing 
IAT.
The risk of septic arthritis following IAT is very low. However, 
while historically the risk estimates for septic arthritis postintra- 
articular GC varied from 0.005% to 0.0002%, a recent study 
showed that the current risk could be higher (0.035 %, three 
per 7900 procedures).26 We have found no studies comparing 
different aseptic techniques during IAT on subsequent risk of 
infection. Surgical gloves, skin preparation with alcohol, iodine 
disinfectant or chlorhexidine and changing needles between 
drawing the drug and injecting it into the joint are indirectly 
supported by their benefit in other common procedures, such as 
blood cultures and surgery.27 28
Patients should be offered local anaesthetic explaining pros and 
cons.
The main reasons for using local anaesthetics in IA T are to 
reduce discomfort during the procedure and to extend pain 
reduction effect. Local anaesthetics may be applied on the skin, 
infiltrated in the subcutaneous tissue, along the needle path into 
the joint, or injected into the joint, alone or mixed with GC. 
Topical anaesthetics such as eutectic mixture of local anaesthetic 
cream, lidocaine 2.5% and pilocarpine 2.5% or ethyl chloride 
spray, can reduce pain from the needle as demonstrated in chil-
dren in one RCT.29 Several TF members suggested ethyl chloride 
spray, a nonsterile coolant aerosol, might increase infection risk 
when not applied correctly, but we failed to find any evidence 
for this. A high- quality SR showed that warmed local anaesthetic 
(37°C) reduces local infiltration pain compared with injecting at 
room temperature, irrespective of whether the local anaesthetic 
was buffered or not.30 Anaesthetic infiltration while advancing 
the needle into the joint does not minimise procedural pain, as 
suggested in a retrospective analysis performed in US- guided 
hip injections for MR arthrography.31 Several RCTs in knee 
and hip OA have shown that the combination of GC and local 
anaesthetic improves pain longer than only injecting local anaes-
thetic.32 33 Some TF members raised concern about the effect of 
lidocaine on cartilage. We found a study, by Ravnihar et al, on 
knee cartilage obtained from biopsies, that showed no differ-
ences in chondrocyte viability and morphology and population 
doublings after a single injection of lidocaine, and we failed to 
identify in vivo evidence of cartilage toxicity.34 One last aspect 
on anaesthetics would be allergic reactions. Patients should be 
asked about previous allergic events prior to the procedure.
Diabetic patients, especially those with suboptimal control, should 
be informed about the risk of transient increased glycaemia 
following IA glucocorticoid injection and advised about the need to 
monitor glucose levels particularly from first to third day.
IA GC can provoke transient hyperglycaemia, which may cause 
risk to patients with diabetes mellitus by raising blood glucose 
to hyperglycaemic levels. One SR of critically low quality, 
including 76 patients, showed that blood glucose levels increase 
during day 1–3 postinjection though no severe adverse events 
such as hyperosmolar hyperglycaemic state or ketoacidosis were 
encountered.35 Twu et al prospectively analysed 70 diabetic 
patients requiring IA GC and observed that preinjection haemo-
globin A1C had a significant effect on postinjection blood, 
whereas corticosteroid dose, body mass index, insulin use and 
the number of injections had no significant effect on the eleva-
tion of blood glucose.36 Also, an RCT showed that extended 
release triamcinolone acetonide may increase glycaemia less than 
the standard triamcinolone acetonide (14.7 mg/dL vs 33.9 mg/
dL),37 and so it could be an alternative for poor controlled 
diabetic patients. Finally, although diabetes predisposes to native 
and prosthetic joint infection,38–40 none of the studies on IA 
GC in patients with diabetics reported postprocedure infec-
tions.35–38 41–43
IAT is not a contraindication in people with clotting/bleeding 
disorders or taking antithrombotic medications, unless bleeding risk 
is high.
Our literature review identified 15 observational studies 
including 1428 patients (1425 haemophilia and 3 Von Will-
ebrand disease) subjected to more than 10 000 procedures (all 
of which were performed after appropriate factor replacement) 
including radioisotopes, triamcinolone, HA and other products, 
revealed only two hemarthroses and three soft- tissue bleeds in 
one study; thus, IAT appears to be a low- bleeding risk procedure 
in patients with clotting- impairing haematological disease.44–57 
Based on seven observational studies, the estimated periproce-
dure bleeding risk in patients on antithrombotic drugs (anti-
platelet agents, low- molecular weight heparin, warfarin or 
direct oral anticoagulants) was found to be between 0% and 
2%.58–63 One of the larger studies, retrospectively reviewed 640 
procedures (arthrocentesis and joint injections) in 514 patients 
taking warfarin; they found no significant difference in early 
and late complications in patients receiving therapeutic warfarin 
(INR 2–3) compared with nontherapeutic levels (INR <2).61 
In another large retrospective study, no bleeding was reported 
in 1050 procedures performed in 483 patients on rivaroxaban 
(52%), apixaban (31%) or dabigatran (17%).62 Several panellists 
suggested that local pressure to prevent bleeding may be more 
important after injecting deeper joints than superficial ones.
IAT may be performed at least 3 months prior to joint replacement 
surgery and may be performed after joint replacement following 
consultation with the surgical team.
We identified six SRs, one of low quality and five of critically low 
quality, assessing safety issues of IA GC prior and following joint 
replacement.64–69 Evidence was not conclusive of an increased 
risk of infection with IA GC injection in the hip or knee prior 
to total joint arthroplasty. Three retrospective studies examined 
whether this was a matter of a ‘safe window’. The rate of pros-
thetic infections 3 months after surgery was significantly larger 
in the groups that had injections 0–3 months prior to total hip or 
knee arthroplasty, but not if the injections were separated from 
the surgery longer than 3 months; however, the difference was 
not strikingly large (from 0.5% to 1.0%, with background risk 
from 1.04% to 2.5%).70–72
Another important issue is whether it is safe to inject GC in 
a prosthetic joint. In a retrospective medical record review that 
aimed to assess the risk of acute infections in patients with total 
knee prosthesis,73 the authors found a 0.6% infection rate in 
1845 GC IA injections performed in 736 patients (1 infection in 
every 625 infiltrations). A recent single- centre retrospective study 
showed no joint infections at a minimum of 1- year follow- up in 
184 patients with total knee prosthesis (31% received two to 
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five GC injections).74 Both studies pointed out that IA GC injec-
tions in prosthetic joints should be avoided in routine practice 
and considered by orthopaedic surgeons after strict screening of 
prosthetic infection.
The shared decision to reinject a joint should take into consideration 
benefits from previous injections and other individualised factors 
(eg, treatment options, compound used, systemic treatment, 
comorbidities…).
IATs have been tested for different doses, frequencies and inter-
vals. However, high- quality studies that aimed to evaluate the 
long- term effect of repeating IA injections are scarce. There are 
no clear evidence- based recommendations as to the appropriate 
number of IA injections from a risk benefit perspective for most 
indications. We found two RCT in knee OA, comparing IA GC 
every 3 months for 2 years versus saline, one showing gain in 
symptoms and no deleterious effect on cartilage volume,75 and 
the other showing no difference in pain and greater progres-
sion of cartilage volume loss with GC.76 A general accepted rule, 
though based on no research evidence, is to avoid more than 
3–4 GC injections in the same joint per year. An SR on long- 
term effect of repetitive IA HA showed sustained or further pain 
reduction with repeated courses of HA and no serious adverse 
effect.77
Avoid overuse of injected joints for 24 hours following IAT; however, 
immobilisation is discouraged.
Most practitioners advise restricted activities. Studies have 
shown that 24–48 hour postinjection immobilisation, such as bed 
rest, joint splinting or bandages, add no benefit compared with 
normal activity after IAT, even when injecting radioisotopes.78–83 
Radioisotopic radiation leakage into extrasynovial tissue may be 
minimised by splinting during 48 hours.78–80
DISCUSSION
Herein, we present the first EULAR evidence- based recommen-
dations to help guide health professionals who perform IAT in 
adult patients with peripheral joint disorders. We established 
5 overarching principles and 11 recommendations addressing: 
patient information; procedure and setting; accuracy; routine 
and special antiseptic care; safety and precautions in special 
populations; efficacy and safety of repeated joint injections; the 
usage of local anaesthetics and aftercare. The main challenge 
faced by the TF has been the complexity of the topic and the 
paucity and controversy of the scientific evidence.
At the first meeting, it was very clear to the TF that there 
was a need for developing practical recommendations prior, 
during and after performing IAT, as this common procedure is 
performed by different clinicians and has not undergone a robust 
expert evidence- based evaluation. This ambitious and complex 
project required not only a well- designed broad systematic liter-
ature review, and an expert international panel, but also feed 
back from a broader group of health professionals and patients. 
We were fully aware that many of the accepted issues had little 
or no scientific support. Hence, we designed the surveys for 
back ground information from health professionals and patients 
coming from EULAR member countries. The respondents’ 
opinions were presented with the results of the SRs for each 
pertinent research question. This helped the TF formulate low 
evidence (1, 2, 4 and 6) and moderately low evidence (5, 8 and 
9) recommendations.
Recommendation 6, addressing the offering of local anaes-
thetics had the lowest agreement. The surveys revealed that 
approximately 50% of the health professional never use local 
anaesthetic, despite the fact that, in their respective survey, 
patients recurrently asked for a less painful or even painless 
procedure.14 The low agreement was possibly due to the lack of 
scientific evidence on the benefit of local anaesthetics.
Recommendations with moderate evidence were 3 and 10. 
Part of recommendation 3 relating to the accuracy of IA injec-
tions says that “if available, imaging guidance, for example, 
ultrasound, may be used to improve accuracy”. This part of the 
recommendation was worded as an open suggestion because 
many units neither have ultrasound machines nor physicians 
trained in joint ultrasonography. Noticeably when injecting a 
radiopharmaceutical, imagining is important to minimise extra-
synovial radiogenic tissue necrosis.84
The identification of evidence was hampered by the large 
number of questions posed, the large number of potential popu-
lations and interventions as well as time constraints. We tackled 
it by using nine sensitive ‘theme’ search strategies and then 
organising the studies into the different questions.
These recommendations assume that ‘best practice’ is the 
rationale for IAT and for the selection of the compound. It was 
out of our scope to study and to compare the efficacy and safety 
of the specific IATs as well as to address the indications for the 
different arthropathies. When looking at contextual factors that 
may influence outcome, such as decrease in joint pain, we found 
that the procedure itself has an important placebo effect.85 This 
should be considered not only in daily practice but also when 
interpreting the results of RCTs comparing IAT with systemic 
therapy or in observational studies on IAT. Another general 
aspect encountered was that the majority of the studies identi-
fied were conducted by orthopaedic surgeons and rehabilitation 
specialists and fewer by rheumatologists, and that most studies 
dealt with IA HA in patients with knee OA, while rheumatolo-
gists predominantly use IA GC.
Despite IAT being an important procedure and widely used 
for more than 70 years, many aspects of IAT still need to be 
assessed to increase our quality of care. These may include safe 
and cost- effective settings and procedures; whether ultrasound 
diagnosis and guidance improve outcome; better RCTs, and 
perhaps a real- life registry of IATs, like the arthroplasty registers.
As a disclaimer, this project was carried out before the 
COVID-19 pandemic outbreak, so it does not include specific 
safety measures to prevent SARS- CoV-2 viral infection nor 
measures to be used when having to deliver IAT to patients with 
COVID-19. Health professionals and patients should follow 
local country regulations and recommendations relating to this 
matter.
We expect these first recommendations to be included in 
different educational programmes, used by patient associations, 
and put into practice via scientific societies to help improve 
uniformity and quality of care when performing IAT in periph-
eral adult joints.
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